Topic 1: Foundations in Opioid Use Disorder (OUD) and OUD Treatment

A Patient’s First Day: Barriers to Treatment, Treatment Initiation Best Practices, and Sample Low-Threshold Clinic

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • ASWB ACE: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Mar 28, 2022
  • Expires: Mar 27, 2025
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    ( Ratings)

A Patient’s First Day: Barriers to Treatment, Treatment Initiation Best Practices, and Sample Low-Threshold Clinic enduring module is a recording from the live Regularly Scheduled Series dated March 4, 2021. If you claimed credit for this session at the live meeting, you should not claim credit for this module. 


Laura C.  Fanucchi Laura C. Fanucchi, MD, MPH
Associate Professor, Medicine
Division of Infectious Diseases
Center on Drug and Alcohol Research
University of Kentucky
Director, UK Addiction Consult and Education Services
Lexington, Kentucky

Needs Statement

Less than 20% of individuals with an opioid use disorder (OUD) receive treatment including medications. Low-threshold medication for opioid use disorder (MOUD) treatment represent a key link between episodes of illness driven by opioid use disorder (OUD) and effective management of OUD.

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers


Upon completion of this activity, participants will be able to:

  • Identify critical challenges facing patients seeking treatment for Opioid Use Disorder (OUD).
  • Describe treatment initiation process requirements and best practices.
  • Describe the features and team structure of a low-threshold OUD clinic and its impact on a patient’s initiation of MOUD treatment.


In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0221-H1.5-UKHC2b

IPE Competencies

  • Values/Ethics for Interprofessional Practice
  • Roles/ Responsibilities
  • Interprofessional Communication
  • Teams and Teamwork

This -based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 general continuing education credit.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.


In collaboration with UK Substance Use Research Priority Area.